Marinomed Biotech AG Leads BCG’s Gender Diversity Index Austria 2020
February 26, 2021
Corporate News

Marinomed Biotech AG (VSE:MARI), a globally operating biopharmaceutical company, announced today that the Company ranks in the first place on Boston Consulting Group’s (BCG) Gender Diversity Index Austria 2020 and is officially Austria’s most diverse company regarding gender composition of corporate boards. The study focused on the 50 largest public companies in Austria by market capitalization. The results are published in the economics magazine trend

Dr. Andreas Grassauer, CEO of Marinomed Biotech AG, commented: “We are very proud to lead this important cross-industry ranking. As a public company, we feel we should lead by example and our efforts in this field can really make a difference: Also, the United Nations recognize gender diversity and equality as important contributions towards sustainable economies, which benefit societies and humanity at large.” Marinomed Biotech AG received 83.4 points out of the 100 points available, which are assigned to an equal distribution of men and women in (supervisory) board positions as well as equal average pay for men and women. In contrast, the 50 Austrian companies received only 33 points in average. With a female share of only 8.9 % on boards, Austria ranks second last of the 27 EU states. “However, there is still much work to do, both at Marinomed and in Austria, in order to reach gender equality and to overcome the gender gap,” Dr. Grassauer added. 

Dr. Eva Prieschl-Grassauer, Chief Scientific Officer and member of the board, commented: “Creating equal opportunities is among Marinomed’s core values. Currently, 70 % of our nearly 50 employees are women and the majority work in research where they contribute to the scientific successes of our technology platforms Carragelose and Marinosolv. We will continue to ensure gender diversity and equal opportunities for all at Marinomed in the future and hope that other companies will follow suit.”

For the BCG Gender Diversity Index Austria 2020, BCG chose companies listed on the Austrian Prime or Standard Market and focused on the 50 largest companies by market capitalization. The index is equally based on the two main factors quantity (share of women in boards) and quality (functional remuneration), each divided in two subcategories. All data used was publicly available.

The full study is available online (in German language only): https://image.bcg-email.com/lib/fe5c15707c62037c771d/m/15/4f6b4708-4bb9-4b07-891d-3d39cc3feda0.pdf



About Marinomed Biotech AG

Marinomed Biotech AG (Korneuburg, Austria) is a biopharmaceutical company listed on the Prime Market of the Vienna Stock Exchange. The company focuses on the development of innovative products based on two patent-protected technology platforms. The Marinosolv® technology platform increases the efficacy of hardly soluble compounds for the treatment of sensitive tissues such as eyes, nose, lung or gastrointestinal tract. The Carragelose® platform comprises innovative patent-protected products for the prophylaxis und treatment of respiratory tract viral infections including SARS-CoV-2. Carragelose® is used in nasal sprays, throat sprays and lozenges, which are sold via international partners in over 40 countries worldwide. Marinomed®, Marinosolv® und Carragelose® are registered trademarks of Marinomed AG. These trademarks may be owned or licensed in select locations only. Further information is available at https://www.marinomed.com/en/technologies-markets/markets. 

For further inquiries contact: 

Dr. Eva Prieschl-Grassauer
Chief Scientific Officer, Marinomed Biotech AG
Hovengasse 25, 2100 Korneuburg, Austria
T +43 2262 90300
E-mail: eva.prieschl@marinomed.com 
http://www.marinomed.com/en

 

International Media Contact
MC Services AG
Dr. Brigitte Keller, Julia Hofmann 
T +49 89 210228 0 
UK: Shaun Brown
M: +44 7867 515 918
E-mail: marinomed@mc-services.eu

Media Contact Austria
Metrum Communications GmbH 
Roland Mayrl
T +43 1 5046987-331
E-Mail: r.mayrl@metrum.at

 

Disclaimer
This press release contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of Marinomed Biotech AG may be identified by the context of such statements or words such as “anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project” and “target”. Forward-looking statements are only valid as of the date they are made and Marinomed Biotech AG does not assume any obligation to update, review or revise any forward-looking statements contained in this press release whether as a result of new information, future developments or otherwise.